📊 EVMN Key Takeaways
Is Evommune, Inc. (EVMN) a Good Investment?
Evommune is a pre-revenue pharmaceutical company burning cash at an unsustainable rate with -$76.4M operating cash flow against only $44.1M in remaining cash reserves. The company generates minimal revenue ($13M) while operating at massive losses (-$81.1M operating income, -$529.8% net margin), indicating either failed commercialization or continued R&D phase without near-term profitability. With current burn rate, cash runway appears limited to approximately 6-7 months without additional financing.
Evommune's fundamentals are very weak: the company is generating only modest revenue against extremely large operating and net losses, with operating and free cash flow deeply negative. While the balance sheet is currently clean and liquid with no meaningful debt, the cash balance appears insufficient relative to the annual cash burn, making future dilution or external financing a significant risk unless operating performance improves materially.
Why Buy Evommune, Inc. Stock? EVMN Key Strengths
- Strong balance sheet with $205.6M stockholders' equity and low leverage (0.00x debt/equity)
- Excellent liquidity position with 8.57x current ratio providing short-term financial flexibility
- Substantial asset base of $224.9M suggesting tangible R&D infrastructure and intellectual property
- Strong liquidity profile in the near term, with current and quick ratios of 8.57x
- Very low leverage and no meaningful long-term debt burden
- Large equity base relative to liabilities, providing some balance sheet flexibility
EVMN Stock Risks: Evommune, Inc. Investment Risks
- Critical cash burn rate of -$76.4M annually with only $44.1M cash remaining creates severe liquidity crisis risk
- Massive negative margins (-623.6% operating, -529.8% net) indicate business model is fundamentally not generating profits at any scale
- Minimal revenue generation of $13M with zero YoY growth suggests failed commercialization, clinical delays, or non-operational status
- Free cash flow of -$76.7M indicates company is consuming capital faster than equity cushion can sustain
- Operating margin of -623.6% and net margin of -529.8% indicate an unsustainable cost structure
- Annual operating cash burn of $76.44M versus $44.06M cash suggests limited runway without new capital
- No revenue growth and continued losses reduce confidence in business model scalability and growth quality
Key Metrics to Watch
- Monthly cash burn rate and runway to insolvency
- Revenue growth trajectory and regulatory approvals/clinical trial progress
- Quarterly operating cash flow trends and operating expense reduction
- Dilution from future financing rounds and equity offerings
- Quarterly operating cash burn versus cash and equivalents
- Revenue growth and improvement in operating loss trajectory
Evommune, Inc. (EVMN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.57x current ratio provides a solid financial cushion.
EVMN Profit Margin, ROE & Profitability Analysis
EVMN vs Healthcare Sector: How Evommune, Inc. Compares
How Evommune, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Evommune, Inc. Stock Overvalued? EVMN Valuation Analysis 2026
Based on fundamental analysis, Evommune, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Evommune, Inc. Balance Sheet: EVMN Debt, Cash & Liquidity
EVMN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Evommune, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-45.29 indicates the company is currently unprofitable.
EVMN Revenue Growth, EPS Growth & YoY Performance
EVMN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $7.0M | -$12.5M | $-8.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Evommune, Inc. Dividends, Buybacks & Capital Allocation
EVMN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Evommune, Inc. (CIK: 0002044725)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EVMN
What is the AI rating for EVMN?
Evommune, Inc. (EVMN) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 91% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EVMN's key strengths?
Claude: Strong balance sheet with $205.6M stockholders' equity and low leverage (0.00x debt/equity). Excellent liquidity position with 8.57x current ratio providing short-term financial flexibility. ChatGPT: Strong liquidity profile in the near term, with current and quick ratios of 8.57x. Very low leverage and no meaningful long-term debt burden.
What are the risks of investing in EVMN?
Claude: Critical cash burn rate of -$76.4M annually with only $44.1M cash remaining creates severe liquidity crisis risk. Massive negative margins (-623.6% operating, -529.8% net) indicate business model is fundamentally not generating profits at any scale. ChatGPT: Operating margin of -623.6% and net margin of -529.8% indicate an unsustainable cost structure. Annual operating cash burn of $76.44M versus $44.06M cash suggests limited runway without new capital.
What is EVMN's revenue and growth?
Evommune, Inc. reported revenue of $13.0M.
Does EVMN pay dividends?
Evommune, Inc. does not currently pay dividends.
Where can I find EVMN SEC filings?
Official SEC filings for Evommune, Inc. (CIK: 0002044725) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EVMN's EPS?
Evommune, Inc. has a diluted EPS of $-11.22.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EVMN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Evommune, Inc. has a STRONG SELL rating with 91% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EVMN stock overvalued or undervalued?
Valuation metrics for EVMN: ROE of -33.5% (sector avg: 15%), net margin of -529.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy EVMN stock in 2026?
Our dual AI analysis gives Evommune, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EVMN's free cash flow?
Evommune, Inc.'s operating cash flow is $-76.4M, with capital expenditures of $235.0K. FCF margin is -589.8%.
How does EVMN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -529.8% (avg: 12%), ROE -33.5% (avg: 15%), current ratio 8.57 (avg: 2).